Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.

← All approvals · Immune & inflammatory · 2024

Leqselvi (deuruxolitinib)

The FDA approved Leqselvi (deuruxolitinib) on July 25, 2024 to treat severe alopecia areata.

Brand name: Leqselvi
Generic name: deuruxolitinib
FDA approval date: July 25, 2024
Approved use (FDA wording): To treat severe alopecia areata
Category on this site: Immune & inflammatory

Official sources

FDA novel drug approvals list
FDA announcement

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.